Azulene Labs Secures $3.4 Million Pre-Seed Round For Drug And Materials Simulation

1 hour ago

3 min read

September 23, 2026

Insider Brief

Azulene Labs raised $3.4 million in pre-seed funding to develop physics-based AI models for drug discovery, materials development and industrial chemistry.
The company says its models use quantum-mechanical training data to improve the accuracy and efficiency of molecular simulations compared with existing AI approaches.
Azulene plans to use the funding to expand its team and product development as it works with biotechnology and industrial chemistry customers.

PRESS RELEASE — Azulene Labs, a startup creating the future of drug and materials development, has raised a $3.4 million pre-seed round. The round was led by Ground State Ventures, with participation from existing Azulene investor Entrada Ventures and angels.

While mechanical and civil engineers design new products with high-precision software, chemistry has traditionally been far more imprecise. For example, even after sixty years of computer modeling, predictions of how tightly a drug sticks to its target protein are still routinely wrong by a factor of a hundred or more.

Azulene Labs is rebuilding the simulation stack to make chemistry and biochemistry modeling truly predictive for the first time. It is building high-accuracy physics-based foundation models that provide around 100 times the efficiency of competitors while being at least 200 times more cost-effective.

“An airplane is specified down to manufacturing tolerances before anyone builds a prototype. A skyscraper is load-tested in simulation before a single beam goes up. These ‘macroscopic’ models are so accurate that you can put enormous trust in them. Chemistry has had nothing like this. Until now.” says Azulene Labs co-founder Nicolas Sawaya.

“Chemistry should work the way aerospace engineering already works, where you design the thing in a computer, you believe the answer, and the physical object behaves as predicted the first time you build it.”

To achieve this, Azulene Labs uses quantum-mechanical training data that produces far more high-quality data and higher-accuracy AI models for the same amount of capital as other approaches.

While there have been significant advances in AI-based chemistry modeling in recent years, existing models routinely produce structures that are deeply inaccurate, or worse, physically impossible. Azulene Labs’ models are constrained to the laws of physics in ways that the current cutting-edge AI models are not.

The technology can make a significant impact on product development across pharma, agriculture, energy storage, plastics, and industrial chemicals.

“Imagine cancer medicines aimed at proteins the industry wrote off as undruggable decades ago; new antibiotics for infections that have stopped responding to everything we have; replacements for the solvents the chemical industry runs on by the megaton, many of which are toxic enough that regulators are phasing them out with no good substitute yet found, or plastics that perform like the ones we use today but break down completely afterward instead of persisting for centuries,” Sawaya says.

Sawaya, who holds a PhD in chemical physics from Harvard, founded Azulene Labs after leading quantum algorithm development for chemistry at Intel Labs. The founding team includes scientists with PhDs from Caltech, Harvard, UC Berkeley, Columbia, and MIPT.

The new funds will be spent on expanding the team and further product development. The company is currently working with end-users in the biotech and industrial chemistry markets.

Ton van ‘t Noordende, founder and General Partner at Ground State Ventures, says:

“What we see in this company is exceptional founder-market fit at a time when the pharma market is hungry for exactly what this incredible team is building. Nicolas is the perfect person to lead Azulene Labs to become the Anthropic of chemistry.”